These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 22002677)
21. Clinical significance of 'double-hit' and 'double-expression' lymphomas. Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842 [TBL] [Abstract][Full Text] [Related]
22. miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma. Zajdel M; Rymkiewicz G; Chechlinska M; Blachnio K; Pienkowska-Grela B; Grygalewicz B; Goryca K; Cieslikowska M; Bystydzienski Z; Swoboda P; Walewski J; Siwicki JK Tumour Biol; 2015 Jul; 36(7):5377-88. PubMed ID: 25677902 [TBL] [Abstract][Full Text] [Related]
23. Detection of MYC rearrangement in high grade B cell lymphomas: correlation of MYC immunohistochemistry and FISH analysis. Lynnhtun K; Renthawa J; Varikatt W Pathology; 2014 Apr; 46(3):211-5. PubMed ID: 24614699 [TBL] [Abstract][Full Text] [Related]
24. Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement. Pienkowska-Grela B; Rymkiewicz G; Grygalewicz B; Woroniecka R; Krawczyk P; Czyz-Domanska K; Walewski J Med Oncol; 2011 Dec; 28(4):1589-95. PubMed ID: 20661666 [TBL] [Abstract][Full Text] [Related]
25. A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome. Soldini D; Montagna C; Schüffler P; Martin V; Georgis A; Thiesler T; Curioni-Fontecedro A; Went P; Bosshard G; Dehler S; Mazzuchelli L; Tinguely M Ann Oncol; 2013 Jan; 24(1):193-201. PubMed ID: 22967991 [TBL] [Abstract][Full Text] [Related]
26. Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements. Yoshida M; Ichikawa A; Miyoshi H; Kiyasu J; Kimura Y; Arakawa F; Niino D; Ohshima K Pathol Int; 2015 Oct; 65(10):519-27. PubMed ID: 26224092 [TBL] [Abstract][Full Text] [Related]
27. Transformation of Follicular Lymphoma to a High-Grade B-Cell Lymphoma With MYC and BCL2 Translocations and Overlapping Features of Burkitt Lymphoma and Acute Lymphoblastic Leukemia: A Case Report and Literature Review. Bischin AM; Dorer R; Aboulafia DM Clin Med Insights Blood Disord; 2017; 10():1179545X17692544. PubMed ID: 28579851 [TBL] [Abstract][Full Text] [Related]
28. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Kramer MH; Hermans J; Wijburg E; Philippo K; Geelen E; van Krieken JH; de Jong D; Maartense E; Schuuring E; Kluin PM Blood; 1998 Nov; 92(9):3152-62. PubMed ID: 9787151 [TBL] [Abstract][Full Text] [Related]
30. Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. McClure RF; Remstein ED; Macon WR; Dewald GW; Habermann TM; Hoering A; Kurtin PJ Am J Surg Pathol; 2005 Dec; 29(12):1652-60. PubMed ID: 16327438 [TBL] [Abstract][Full Text] [Related]
31. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. Landsburg DJ; Falkiewicz MK; Petrich AM; Chu BA; Behdad A; Li S; Medeiros LJ; Cassaday RD; Reddy NM; Bast MA; Vose JM; Kruczek KR; Smith SE; Patel P; Hernandez-Ilizaliturri F; Karmali R; Rajguru S; Yang DT; Maly JJ; Blum KA; Zhao W; Vanslambrouck C; Nabhan C Br J Haematol; 2016 Nov; 175(4):631-640. PubMed ID: 27469075 [TBL] [Abstract][Full Text] [Related]
32. Role of immunohistochemistry in the era of genetic testing in MYC-positive aggressive B-cell lymphomas: a study of 209 cases. Agarwal R; Lade S; Liew D; Rogers TM; Byrne D; Feleppa F; Juneja S; Westerman DA J Clin Pathol; 2016 Mar; 69(3):266-70. PubMed ID: 26307073 [TBL] [Abstract][Full Text] [Related]
33. A novel five-way translocation, t(3;9;13;8;14)(q27;p13;q32;q24;q32), with concurrent MYC and BCL6 rearrangements in a primary bone marrow B-cell lymphoma. Yamamoto K; Matsuoka H; Yakushijin K; Funakoshi Y; Okamura A; Hayashi Y; Minami H Cancer Genet; 2011 Sep; 204(9):501-6. PubMed ID: 22018272 [TBL] [Abstract][Full Text] [Related]
34. Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. Swerdlow SH Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):90-9. PubMed ID: 25696840 [TBL] [Abstract][Full Text] [Related]
35. [Immunophenotyping and molecular genetic analysis of diffuse large B-cell lymphoma]. Han YS; Xue YQ; Yang HY; Zhang J; Pan JL Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):143-7. PubMed ID: 23568722 [TBL] [Abstract][Full Text] [Related]
36. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches. Petrich AM; Nabhan C; Smith SM Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588 [TBL] [Abstract][Full Text] [Related]
37. The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma. Lin P; Medeiros LJ Curr Hematol Malig Rep; 2013 Sep; 8(3):243-52. PubMed ID: 23892979 [TBL] [Abstract][Full Text] [Related]
38. A Diagnostic Approach to the Identification of Burkitt-like Lymphoma With 11q Aberration in Aggressive B-Cell Lymphomas. Horn H; Kalmbach S; Wagener R; Staiger AM; Hüttl K; Mottok A; Bens S; Traverse-Glehen A; Fontaine J; Siebert R; Rosenwald A; Ott G Am J Surg Pathol; 2021 Mar; 45(3):356-364. PubMed ID: 33136583 [TBL] [Abstract][Full Text] [Related]
39. Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases. Pina-Oviedo S; Bellamy WT; Gokden M Ann Diagn Pathol; 2020 Oct; 48():151610. PubMed ID: 32889391 [TBL] [Abstract][Full Text] [Related]
40. Tourneret A; Alame M; Rigau V; Bauchet L; Fabbro M; De Oliveira L; Cacheux V; Costes V; Lacheretz-Szablewski V J Clin Pathol; 2021 Oct; 74(10):650-656. PubMed ID: 32912960 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]